Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

S. Finn, Richard; Qin, Shukui; Ikeda, Masafumi; R. Galle, Peter; Ducreux, Michel; Kim, Tae‐You; Kudo, Masatoshi; В. Бредер, В.; Merle, Philippe; O. Kaseb, Ahmed; Li, Daneng; Verret, Wendy; Xu, Derek-Zhen; Hernandez, Sairy; Liu, Juan; Huang, Chen; Mulla, Sohail; Wang, Yulei; Yeong Lim, Ho; X. Zhu, Andrew; Cheng, Ann‐Lii

doi:10.1056/nejmoa1915745

Public

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Published in New England Journal of Medicine • May 13, 2020

Authors:

Richard S. Finn

Shukui Qin

Masafumi Ikeda

Abstract

BACKGROUND: The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS: In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had...

Subject

Atezolizumab

Bevacizumab

Hepatocellular carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!